Study of P3914 to Evaluate the Safety, Tolerability, Food Effect & Pharmacokinetics in Healthy Male Subjects and Efficacy & Safety of P3914 in Patients With Acute Dental Pain

This study has been terminated.
Sponsor:
Information provided by (Responsible Party):
Piramal Enterprises Limited
ClinicalTrials.gov Identifier:
NCT01339156
First received: April 15, 2011
Last updated: November 21, 2012
Last verified: November 2012
  Purpose

P3914 a pro-drug of Naproxen, characterized by naproxen (COX inhibiting moiety) linked to a NO moiety is intended for the treatment of pain and inflammation. The rationale behind development of P3914 is to maintain the analgesic, antipyretic and anti-inflammatory activity of naproxen and enhance GI safety by virtue of release of NO besides with no major effect on blood pressure on long-term administration.


Condition Intervention Phase
Acute Dental Pain
Drug: P3914
Drug: Placebo
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Randomized, Double-blind, Placebo-controlled Phase I-Ib Study of P3914 to Evaluate the Safety, Tolerability, Food Effect & Pharmacokinetics in Healthy Male Subjects and Efficacy & Safety of P3914 in Patients With Acute Dental Pain

Further study details as provided by Piramal Enterprises Limited:

Primary Outcome Measures:
  • Vital signs- systolic and diastolic blood pressure, pulse rate and oral body temperature. [ Time Frame: Defined in description ] [ Designated as safety issue: Yes ]

    Vital signs will be measured using DASH 4000. Predose vital signs will be recorded within 30 minutes prior to dosing.

    Part A: pre-dose & at 1,2,3,4,5,6,8,12,16,24,48,72,96 & 120 hrs post dose. Part B:pre-dose on Day 2 to Day 13,predose & at 4 and 12 hrs post-dose on Days 1 &14.Part:C: pre-dose & at 1, 2, 3, 4, 5,6,8,12,24,48,72,96 & 120 hrs postdose.Part D:predose & at 0.5,1,2,4,&8 hrs post dose.



Secondary Outcome Measures:
  • Pain intensity using 100 mm Visual analog scale [ Time Frame: immediately before administration of study drug and at 0.50, 1.00, 1.50, 2.00, 2.50, 3.00, 4.00, 5.00, 6.00, 7.00, and 8.00 hrs post-dose, and immediately before administration of rescue analgesia (if any). ] [ Designated as safety issue: No ]
    This assessment will be carried out in Part D of the study.

  • Pharmacokinetic assessment for Part A [ Time Frame: within 15 min prior to dosing. Post-dose blood samples will be drawn at 0.25, 0.50, 1, 2, 3, 3.50, 4, 4.50, 5, 5.50, 6, 8, 10, 12, 16, 24, 36, 48, 72, 96 & 120 hrs following drug administration. ] [ Designated as safety issue: No ]
    The concentration time data generated for P3914, naproxen and nitrate/nitrite levels will be used to calculate the following pharmacokinetic parameters as appropriate using non-compartmental analysis tool Tmax, Cmax, AUC0-t, AUC0-inf, AUC0-24h, % AUC Extrapolated, T1/2, kel, CL, Vz.

  • Pharmacokinetic assessment for Part C [ Time Frame: within 15 min prior to dosing. Post-dose samples will be drawn at 0.25, 0.50, 1, 2, 3, 3.50, 4, 4.50, 5, 6, 8, 10, 12, 24, 48, 72, 96 & 120 hrs following drug administration. ] [ Designated as safety issue: No ]
    The concentration time data generated for P3914, Naproxen and nitrate/nitrite levels will be used to calculate the following pharmacokinetic parameters as appropriate using non-compartmental analysis tool:• Tmax, Cmax, AUC0-t, AUC0-inf, T1/2, and kel.

  • Pharmacokinetic assessment for Part B [ Time Frame: within 15 min prior to dosing on Day 1, 6, 9, 13&14. Post-dose blood samples at 0.25, 0.50, 1, 2, 3, 3.50, 4, 4.50, 5, 5.50, 6, 8, 10, 12, 16& 24 hrs following drug administration on Day 1 & Day 14 and 48 hrs post-dose on Day 16 ] [ Designated as safety issue: No ]

    The concentration time data generated for P3914, Naproxen and and nitrate/nitrite levels will be used to calculate the following pharmacokinetic parameters (as appropriate) using non-compartmental analysis tool:

    Tmax, Cmax, AUC0-t, AUC0-inf, AUC0-24h, T1/2, kel, CL, Vz for Day 1 AND Cmax,ss, AUC0-τ,ss, Cmin,ss, Tmax,ss, Cavg,ss Swing, Percent Fluctuation, t1/2 and Kel for Day 14.


  • Pharmacokinetic assessment for Part D [ Time Frame: within 15 min prior to dosing. Post-dose blood samples of at 0.50, 1, 2, 3, 3.50, 4, 4.50, 5, 5.50, 6 and 8 hrs following drug administration ] [ Designated as safety issue: No ]
    The concentration time data generated for P3914, Naproxen and nitrate/nitrite levels will be used to calculate the following pharmacokinetic parameters as appropriate using non-compartmental analysis tool:Tmax, Cmax, AUC0-t, AUC0-inf, T1/2, and kel.


Enrollment: 46
Study Start Date: June 2011
Study Completion Date: June 2012
Primary Completion Date: November 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: P3914 Drug: P3914

Part A:

The subjects will be fasted overnight for at least 10 hrs.The drug will be administered orally to each subject in sitting posture.

Part B:

Dosing will start on Day 1. Each subject will receive the investigational product under fasting conditions for 14 days (Days 1 to 14).

The investigational product will be administered orally to each subject with 240 mL of water.

Part C:

Dosing will take place on Day 1 of each study period. Each subject will receive a single oral dose.

For administration of P3914 tablets subjects will be required to fast for 10 hrs prior to dosing.

Part D:

Patients will be fasted for at least 4-6 hrs. The investigational product will be administered orally to each subject in sitting posture on day 1 within 6 hrs of first administration of anesthesia (day of dental surgery).

Placebo Comparator: Placebo Drug: Placebo

Part A:

The subjects will be fasted overnight for at least 10 hrs. The investigational product (allocated as per the randomisation schedule) will be administered orally to each subject in sitting posture.

Part B:

Dosing will start on Day 1. It is planned that each subject will receive the investigational product under fasting conditions for 14 days (Days 1 to 14).

The investigational product (allocated as per the randomisation schedule) will be administered orally to each subject with 240 mL of water.

Part D:

Patients will be fasted for at least 4-6 hrs. The investigational product (allocated as per the randomisation schedule) will be administered orally to each subject in sitting posture on day 1 within 6 hrs of first administration of anesthesia (day of dental surgery).


  Eligibility

Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • for Part A, Part B and Part C

    1. Male subjects aged between 18 and 45 years (including both) with Body Mass Index between 18 to 25 kg/m2 (including both).
    2. Subjects with normal health as determined by personal medical history, clinical examination and laboratory examinations within the clinically acceptable normal range.
    3. Subjects having clinically acceptable 12-lead electrocardiogram (ECG).
    4. Subjects having clinically acceptable X-Ray chest (P/A view).
    5. Subjects having clinically acceptable endoscopy.
    6. Have a negative urine screen for drugs of abuse (including amphetamines, barbiturates, benzodiazepines, marijuana, cocaine, and morphine).
    7. Have negative alcohol breath test.
    8. Subjects willing to adhere to the protocol requirements and to provide written informed consent.

Part D:

Patients with acute postoperative dental pain (at least moderate in severity or score of 40 mm on VAS) after removal of an impacted third mandibular molar will be selected for study participation, if they meet the following criteria:

  1. Male patients aged between 18 and 60 years (including both).
  2. Patients with acute postoperative dental pain (at least moderate in severity or score of 40 mm on Visual Analogue Scale)
  3. Patients with otherwise normal health as determined by personal medical history, clinical examination and laboratory examinations within the clinically acceptable normal range.
  4. Patients having clinically acceptable 12-lead electrocardiogram (ECG).
  5. Patients having clinically acceptable chest X-Ray (P/A view).
  6. Patients having clinically acceptable endoscopy.
  7. Have a negative urine screen for drugs of abuse (including amphetamines, barbiturates, benzodiazepines, marijuana, cocaine, and morphine).
  8. Have negative alcohol breath test.
  9. Patients willing to adhere to the protocol requirements and to provide written informed consent.

Exclusion Criteria:

  • Part A, Part B and Part C:

    1. Hypersensitivity to NSAIDs or nitrodonating drugs.
    2. History or presence of significant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, endocrine, immunological, dermatological, neurological or psychiatric disease or disorder.
    3. Any treatment which could bring about induction or inhibition of hepatic microsomal enzyme system within one month of the study starting.
    4. History or presence of significant gastric and/or duodenal ulceration including the last three months or gastroduodenal bleeding including the last six months prior to the screening visit.
    5. History of peptic ulceration or significant dyspepsia as judged by the investigator.
    6. Endoscopy finding of gastric or duodenal ulcer at baseline. Erosive esophagitis or other endoscopic appearance that constitutes a risk to the subject, if included in the study, as judged by the investigator.
    7. Have positive test for Helicobacter pylori infection.
    8. Orthostatic hypotension with a systolic blood pressure drop of ≥ 25 mm Hg and/or a diastolic blood pressure drop of ≥ 15 mm Hg within 5 minutes of standing when changing from supine to erect position.
    9. A history of renal impairment, or a glomerular filtration rate (GFR) <60 mL/min or, at visit 1, a serum creatinine value >140 mol/L.
    10. Use of aspirin, H2 antagonists, antacids, misoprostol, proton pump inhibitors, sucralfate including two weeks prior to the screening visit.
    11. Subjects currently taking sildenafil, anticoagulants or ticlopidine, nitrates, nitrovasodilating drugs (e.g. nitroglycerin, isosorbide dinitrate, isosorbide mononitrate, glycerin trinitrate), diuretics (in a dose potentially leading to volume depletion).
    12. Use of any prescribed medication during last two weeks or OTC medicinal products (including herbal/traditional medicine preparations) during the last one week prior to initiation of study.
    13. History or presence of significant alcoholism or drug abuse in the past one year.
    14. Positive screening test for any one or more: HIV, Hepatitis B and Hepatitis C.
    15. History or presence of smoking or use of other tobacco, pan, gutkha products since last six months.
    16. History or presence of significant asthma, urticaria or other allergic reactions.
    17. History or presence of significant thyroid disease, adrenal dysfunction, organic intracranial lesion such as pituitary tumour.
    18. Difficulty in swallowing solids like tablets or capsules.
    19. History or presence of cancer.
    20. Difficulty with donating blood.
    21. Major illness during three months before screening.
    22. Participation in a drug research study within past three months.
    23. Donation of blood in the past three months before screening.

For Part D:

  1. Hypersensitivity to NSAIDs or nitrodonating drugs.
  2. History or presence of significant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, endocrine, immunological, dermatological, neurological or psychiatric disease or disorder.
  3. Any treatment which could bring about induction or inhibition of hepatic microsomal enzyme system within 1 month of the study starting.
  4. History or presence of significant gastric and/or duodenal ulceration including the last three months or gastroduodenal bleeding including the last six months prior to the screening visit.
  5. History of peptic ulceration or significant dyspepsia as judged by the investigator.
  6. Endoscopy finding of gastric or duodenal ulcer at baseline. Erosive esophagitis or other endoscopic appearance that constitutes a risk to the subject, if included in the study, as judged by the investigator.
  7. Have positive test for Helicobacter pylori infection.
  8. Orthostatic hypotension with a systolic blood pressure drop of ≥ 25 mm Hg and/or a diastolic blood pressure drop of ≥ 15 mm Hg within 5 minutes of standing when changing from supine to erect position.
  9. A history of renal impairment, or a glomerular filtration rate (GFR) <60 mL/min or, at visit 1, a serum creatinine value >140 mol/L.
  10. Use of aspirin, H2 antagonists, antacids, misoprostol, proton pump inhibitors, sucralfate including two weeks prior to the screening visit.
  11. Patients currently taking sildenafil, anticoagulants or ticlopidine, nitrates, nitrovasodilating drugs (e.g. nitroglycerin, isosorbide dinitrate, isosorbide mononitrate, glycerin trinitrate), diuretics (in a dose potentially leading to volume depletion).
  12. Use of analgesics in the 48 hrs preceding the day of dental surgery except use of acetaminophen until midnight on the day before surgery.
  13. Patients with oral surgery in the 30 days before the pre-study visit.
  14. Use of any prescribed medication during last two weeks or OTC medicinal products (including herbal preparations) during the last one week prior to initiation of study.
  15. History or presence of significant alcoholism or drug abuse in the past one year.
  16. Positive screening test for any one or more: HIV, Hepatitis B and Hepatitis C.
  17. History or presence of smoking or use of other tobacco, pan, gutkha products since last 06 months.
  18. History or presence of significant asthma, urticaria or other allergic reactions.
  19. History or presence of significant thyroid disease, adrenal dysfunction, organic intracranial lesion such as pituitary tumour.
  20. Difficulty in swallowing solids like tablets or capsules.
  21. History or presence of cancer.
  22. Difficulty with donating blood.
  23. Major illness during three months before screening.
  24. Participation in a drug research study within past three months.
  25. Donation of blood in the past three months before screening.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01339156

Sponsors and Collaborators
Piramal Enterprises Limited
Investigators
Principal Investigator: Dr. Dharmesh Domadia Veeda Clinical research private limited
  More Information

No publications provided

Responsible Party: Piramal Enterprises Limited
ClinicalTrials.gov Identifier: NCT01339156     History of Changes
Other Study ID Numbers: P3914/48/10
Study First Received: April 15, 2011
Last Updated: November 21, 2012
Health Authority: India: Ministry of Health

Keywords provided by Piramal Enterprises Limited:
Safety
Tolerability
Food Effect
Pharmacokinetics

Additional relevant MeSH terms:
Toothache
Tooth Diseases
Stomatognathic Diseases
Facial Pain
Pain
Signs and Symptoms

ClinicalTrials.gov processed this record on August 18, 2014